Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Two BI 3034701 Treatments in Healthy Participants
NCT07837648Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 3034701 (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to the last quantifiable data point up to 19 days and Maximum measured concentration up to 19 days. Started Oct 2026; status: recruiting.
02
Drugs
BI 3034701
Beyond the preview
Go deeper on NCT07837648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07837648.